Eleven Biotherapeutics major shareholder Jafco Super V3 Investment Limi Sells 1,165 Shares (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi unloaded 1,165 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $11.54, for a total transaction of $13,444.10. Following the transaction, the insider now directly owns 2,121,526 shares of the company’s stock, valued at approximately $24,482,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded down 1.49% during mid-day trading on Thursday, hitting $11.24. The stock had a trading volume of 24,466 shares. Eleven Biotherapeutics has a 52-week low of $9.502 and a 52-week high of $19.333. The stock has a 50-day moving average of $11.89 and a 200-day moving average of $12.96. The company’s market cap is $173.0 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last released its earnings data on Wednesday, August 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.